Loading…
Loading…
CALA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CALA and 80,000+ other tickers.
See exactly how CALA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CALA and 80,000+ other tickers.
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Vistance Networks, Inc. (NASDAQ: VISN), a global leading provider of intelligent network solutions, today reported results for the quarter ended June 30, 2026.*
Calithera Biosciences, Inc. (NASDAQ: CALA - Get Free Report)'s share price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $0.00 and traded as high as $0.0001. Calithera Biosciences shares last traded at $0.0001, with a volume of 887 shares changing hands. Calithera Biosciences
Institutional and Insider Ownership 0.1% of Merck KGaA shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Earnings and Valuation This table compares Calithera Biosciences and
Calithera Biosciences, Inc. (NASDAQ: CALA - Get Free Report)'s stock price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.00 and traded as high as $0.0002. Calithera Biosciences shares last traded at $0.0002, with a volume of 235 shares trading hands. Calithera Biosciences
Unified structure for U.S., Canada & CALA under Satya Anand's leadership; Neal Jones to lead EMEA; Federico "Fede" Greppi to head CALA; retirements of Marriott veterans Liam Brown and Brian King announced. BETHESDA, Md.